Zacks Investment Research lowered shares of Editas Medicine (NASDAQ:EDIT) from a hold rating to a sell rating in a research report report published on Tuesday.

According to Zacks, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. “

EDIT has been the topic of several other research reports. ValuEngine lowered Editas Medicine from a hold rating to a sell rating in a research report on Wednesday, October 25th. BidaskClub upgraded Editas Medicine from a hold rating to a buy rating in a research report on Wednesday, December 27th. Cann reiterated a hold rating on shares of Editas Medicine in a report on Tuesday, November 7th. Morgan Stanley reiterated an equal weight rating and issued a $28.00 price target (up previously from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. Finally, Cowen reiterated a buy rating on shares of Editas Medicine in a report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $26.73.

Shares of Editas Medicine (EDIT) traded up $1.15 during trading on Tuesday, hitting $31.17. The company had a trading volume of 1,530,600 shares, compared to its average volume of 2,274,917. Editas Medicine has a 52 week low of $13.12 and a 52 week high of $36.00. The company has a current ratio of 10.12, a quick ratio of 10.12 and a debt-to-equity ratio of 0.19. The company has a market cap of $1,390.00 and a price-to-earnings ratio of -9.62.

Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Tuesday, November 7th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. The business had revenue of $6.28 million for the quarter, compared to the consensus estimate of $2.66 million. During the same quarter in the previous year, the company earned ($0.59) EPS. The firm’s revenue for the quarter was up 553.0% on a year-over-year basis. analysts predict that Editas Medicine will post -2.92 earnings per share for the current fiscal year.

In other news, CFO Andrew A. F. Hack sold 5,000 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $24.81, for a total value of $124,050.00. Following the completion of the sale, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at $124,050. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Katrine Bosley sold 8,333 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $23.64, for a total value of $196,992.12. Following the completion of the sale, the insider now directly owns 1,393,322 shares of the company’s stock, valued at $32,938,132.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,310 shares of company stock worth $1,689,449. Corporate insiders own 19.40% of the company’s stock.

Institutional investors have recently modified their holdings of the company. First Midwest Bank Trust Division purchased a new stake in shares of Editas Medicine in the third quarter worth approximately $1,349,000. Greenwoods Asset Management Ltd purchased a new stake in shares of Editas Medicine during the second quarter valued at approximately $1,191,000. American Century Companies Inc. purchased a new stake in shares of Editas Medicine during the third quarter valued at approximately $7,497,000. Bank of New York Mellon Corp increased its position in shares of Editas Medicine by 123.8% during the second quarter. Bank of New York Mellon Corp now owns 142,122 shares of the company’s stock valued at $2,385,000 after acquiring an additional 78,632 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Editas Medicine during the second quarter valued at approximately $285,000. 65.70% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/editas-medicine-edit-stock-rating-lowered-by-zacks-investment-research/1801661.html.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.